GigaGen
  • Our Company
    • Team
    • News
  • Our Science
    • Surge and Magnify Technologies
    • Publications, Scientific Posters & Presentations
  • Pipeline
    • Oncology
    • Recombinant Polyclonals
  • Careers
  • Contact
  • Menu Menu

News Archive

GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development

05/19/2022

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the publication of a research article titled, “Predicting antibody binders and generating synthetic antibodies using deep learning,” in the peer-reviewed journal mAbs. The article demonstrates the potential of GigaGen’s machine […]

Read more

GigaGen Licenses ProteoNic’s 2G UNic Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates

09/30/2021

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed a license agreement with Dutch biotech ProteoNic B.V. for the use of its premium 2G UnicTM technology platform to enable high-yield production of GigaGen’s mono- and […]

Read more

BioSpace: An In-Depth Look at Innovation on Cancer Research Day

09/24/2021

September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead. From cancer immunotherapy to precision medicine and the discovery of novel targets and mutations, there is much hope on the horizon, and BioSpace spoke with a few of the people leading […]

Read more

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

08/11/2021

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today the first patient has been dosed in its Phase 1 clinical trial of GIGA-2050, the company’s recombinant hyperimmune polyclonal antibody […]

Read more

GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564

07/14/2021

SOUTH SAN FRANCISCO, Calif., July 14, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research in bioRxiv entitled, “Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy.” The […]

Read more

GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies

05/25/2021

SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal […]

Read more

GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology

04/15/2021

SOUTH SAN FRANCISCO, Calif., April 15, 2021 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Generation of recombinant hyperimmune globulins from diverse B cell repertoires,” in the peer-reviewed journal Nature Biotechnology. […]

Read more

GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting

03/23/2021

SOUTH SAN FRANCISCO, Calif., March 23, 2021 (GLOBE NEWSWIRE) — GigaGen, a biotechnology company advancing transformative antibody drugs for immune deficiency, infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it will present an abstract in a poster session at the 2021 American Association for Cancer Research (AACR) […]

Read more

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

03/09/2021

BARCELONA, Spain, March 9, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P;NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million. GigaGen […]

Read more

GigaGen Announces Publication in the Peer-Reviewed Journal mAbs

10/20/2020

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today publication of a peer-reviewed article titled, “Affinity maturation of antibodies by combinatorial codon mutagenesis versus error-prone PCR,” in the peer-reviewed journal mAbs. The publication is available online here. GigaGen’s newly published data details the technical […]

Read more

GigaGen Initiates Large-Scale Manufacturing of First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050

09/09/2020

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today the company has initiated large-scale manufacturing of its first-in-class recombinant hyperimmune drug for COVID-19, GIGA-2050, in collaboration with two partners for Good Manufacturing Practice (GMP), […]

Read more

GEN: Drug Targets Identified More Discerningly

09/01/2020

“One of the reasons we perform single-cell approaches is they allow us to pick up subtle differences that would be missed with more conventional tools,” says David S. Johnson, PhD, CEO and co-founder of GigaGen, a company that specializes in microfluidics and molecular genomics. Two GigaGen platforms, Surge and Magnify, can facilitate the development of […]

Read more

BioCentury: GigaGen aims to overcome supply limits, boost potency with recombinant convalescent sera substitute

08/12/2020

GigaGen is developing polyclonal antibodies for COVID-19 and other infectious diseases that could be more potent and easier to supply than convalescent plasma. GigaGen Inc. plans to submit an IND for its COVID-19 treatment, GIGA-2050, by year-end. It calls GIGA-2050 a recombinant hyperimmune product, and said it is akin to recombinant convalescent sera. GigaGen showed […]

Read more

KPIX-TV (CBS): Bay Area Biotech Company Takes New Approach in COVID-19 Treatment

08/10/2020

A South San Francisco biotech firm has come up with a way to make a COVID-19 therapy without relying on repeat antibody donors using a new class of drugs called “recombinant hyperimmunes.” Ken Bastida reports. (8-10-20) Watch the tv segment.

Read more

Fierce Biotech: GigaGen’s polyclonal antibody against COVID-19 outperforms plasma in lab tests

08/10/2020

Blood collected from survivors of COVID-19 has been used to identify antibodies against the disease, which have been turned into experimental drugs to fight it. But it’s not an easy process. So back in March, San Francisco startup GigaGen decided to test a technology it developed to rapidly identify disease-fighting antibodies against SARS-CoV-2, the virus […]

Read more

BioSpace: GigaGen Publishes Data on New Recombinant Hyperimmune Drug Class as COVID-19 Therapy

08/10/2020

Convalescent therapy has been touted as a fast, effective response to COVID-19, but a new therapy by GigaGen Inc. could be even more promising. GIGA-2050, a new class of drug called a recombinant hyperimmune, offers 100-fold higher potency than convalescent serum therapy. “GIGA-2050 is a mix of 12,500 different antibody sequences selected from 16 exceptional […]

Read more

GigaGen Announces Publication of Research Describing a New Class of Drugs, Recombinant Hyperimmunes, Including its Novel COVID-19 Therapy, GIGA-2050

08/10/2020

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today a new submission to bioRxiv, titled, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs.” In this study, GigaGen presents a novel […]

Read more

GigaGen to Present at the Inaugural LifeSci Partners Private Company Virtual Summer Symposium

07/29/2020

SOUTH SAN FRANCISCO, Calif., July 29, 2020 (GLOBE NEWSWIRE) — GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, today announced that it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place on August 4-5, 2020. Read the full press release.

Read more

BioPharm International: Plasma-Based Antibody Therapies Battle Against COVID-19

06/01/2020

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients. Read the full story.

Read more

San Francisco Business Times: Biotech adapts to new working conditions in the age of Covid-19

05/26/2020

Read the full story.

Read more
Page 1 of 512345

Latest Tweets

GigaGenFollow

Billions of immune cells in your bloodstream fight disease on a daily basis. GigaGen turns these cells into life-saving medical therapies.

GigaGen
GigaGen@gigageninc·
19 May

We are happy to announce the publication of our latest peer-reviewed research article demonstrating the potential of our machine learning platform to improve antibody drug discovery and development. Learn more in our press release here: https://bit.ly/3MpERvb

Reply on Twitter 1527341245416165393Retweet on Twitter 15273412454161653931Like on Twitter 15273412454161653932Twitter 1527341245416165393
GigaGen@gigageninc·
18 May

This month is #NationalCancerResearchAwareness Month, led by @AACR. At GigaGen we’d like to highlight the importance of lifesaving research to the millions of people living with #cancer. Learn more about this day here: https://bit.ly/3rQGR7n #ResearchSavesLives

Reply on Twitter 1526910761783771137Retweet on Twitter 15269107617837711373Like on Twitter 15269107617837711374Twitter 1526910761783771137
GigaGen@gigageninc·
10 May

Our VP of Oncology, Erica Stone, Ph.D., participated this past weekend at the Immunology 2022 conference, hosted by @ImmunologyAAI! The conference featured speakers from around the world leading the way in the field of #immunology. #AAI2022

Reply on Twitter 1524011494505127936Retweet on Twitter 1524011494505127936Like on Twitter 15240114945051279364Twitter 1524011494505127936
GigaGen@gigageninc·
4 May

This weekend, our VP of Oncology, @StoneEL2, will be at @ImmunologyAAI’s Immunology 2022 conference. She’ll participate on a career discussion panel & will chair a session on next generation immunologic therapies. Learn more & register: https://bit.ly/3OTgwQ7 #AAI2022

Reply on Twitter 1521837165197631488Retweet on Twitter 15218371651976314881Like on Twitter 15218371651976314883Twitter 1521837165197631488
GigaGen@gigageninc·
20 Apr

Our leading #antibody drug candidate targets #CTLA4, a clinically validated #oncology target, and has a unique profile with the potential to overcome effectiveness & safety issues from current therapies. Learn more: https://bit.ly/3Kzlejz

Reply on Twitter 1516763956672671751Retweet on Twitter 1516763956672671751Like on Twitter 1516763956672671751Twitter 1516763956672671751
© Copyright 2022 GigaGen. All Rights Reserved.
  • Twitter
  • LinkedIn
Scroll to top